English | 简体中文 | 繁體中文 | 한국어 | 日本語
2025年4月10日 13時57分 JST
Share:
Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy

SINGAPORE, Apr 10, 2025 - (ACN Newswire) - April 9, Hebe Biotechnology Pte Ltd (“Hebe Bio”), a Singapore-based innovator in metabolic health therapeutics, today announced the appointment of Hannes Hentze, PhD, MBA as Chief Development Officer (CDO), effective April 1, 2025. Dr. Hentze will lead the global development strategy for the company’s next-generation GLP-1 receptor agonist (GLP-1 RA), a cutting-edge weight loss therapy designed to enhance efficacy and tolerability, addressing the global obesity challenge.

Strategic Leadership for a Transformative Therapy

Dr. Hentze brings over two decades of experience in pharmaceutical development, specializing in oncology, metabolic disorders, and biologics. His background spans academic research (IMCB, NTU), biotech ventures (S*BIO, ES Cell International, ASLAN), and large pharmaceutical players (Schering-Plough, MSD). Most recently, he served as Associate Director of Translational Sciences at EDDC (A*STAR).

At Hebe Bio, Dr. Hentze will spearhead preclinical and translational development, guiding clinical trial readiness, regulatory strategy, and strategic partnerships to accelerate the GLP-1 RA program’s global commercialization.

Sam Lim, MD, PhD, MBA, CEO of Hebe Bio, remarked, “We are thrilled to welcome Hannes to our leadership team. His deep expertise in metabolic drug development and his visionary approach align perfectly with our mission to deliver transformative therapies. His leadership will be pivotal as we accelerate our GLP-1 RA candidate, which has the potential to redefine standards in weight management and healthspan extension.”

Advancing Innovation in Metabolic Health

Hebe Bio’s GLP-1 RA therapy integrates cutting-edge science to optimize fat loss in the context of maintaining muscle mass, while minimizing common side effects associated with existing therapies. Preclinical data on Hebe Bio’s lead molecules have demonstrated superior efficacy and tolerability, positioning it as a next-generation solution for truly sustainable, healthspan-extending weight loss therapy.

Dr. Hentze expressed enthusiasm about his new role at Hebe Bio: “Joining Hebe Bio is a unique opportunity to make a real impact in a critical area of global health. Our GLP-1 RA candidate has the potential to shift the obesity treatment paradigm, and I look forward to collaborating with the exceptional Hebe Bio team, and our global partners to bring this therapy to patients worldwide.”

About Hebe Biotechnology Pte Ltd

Hebe Biotechnology is a Singapore-headquartered biopharmaceutical company dedicated to pioneering next-generation therapies for metabolic and chronic diseases. By combining advanced research with strategic global partnerships, Hebe Bio is committed to delivering patient-centric solutions that address unmet medical needs.

Media Contact:

Ms Kung
Bright International Communications Limited
Email: ir@brightcommns.com
Mobile: +852 4637 1627
Website: www.hebebio.sg



トピック: Press release summary
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
 
June 25, 2025 22:27 HKT/SGT
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange 
June 25, 2025 19:00 HKT/SGT
LLVisionがソウルでAR翻訳メガネの新モデル「Leion Hey2」 を世界初披露:日常生活に革新をもたらすAI翻訳 
June 25, 2025 13:00 HKT/SGT
米アンソロピック、東京にAPAC地域初の拠点開設 日本企業からの需要増を受けて日本語版「クロード」提供へ 
June 25, 2025 11:30 HKT/SGT
テクニカ・ゼンとBSI Professional Services Japan、日本企業のAIガバナンスのさらなる強化に向けて、新たに、AIリテラシー/ガバナンスの包括的な研修サービスの提供を開始 
June 25, 2025 10:00 HKT/SGT
富士通、誰もが安心して暮らせる仮設住宅の実現に向けて、ミリ波レーダを活用した高齢者見守りの実証実験を実施 
June 24, 2025 10:30 HKT/SGT
YCP Releases New White Paper on the Shift to Affiliate Marketing in Southeast Asia 
June 23, 2025 12:00 HKT/SGT
Shaping a New Platform for Global Growth Discussed at Open Dialogue within SPIEF-2025 
June 20, 2025 23:00 HKT/SGT
Shaping a New Platform for Global Growth がSPIEF-2025のオープンダイアログで議論される 
June 20, 2025 23:00 HKT/SGT
Global Economic Shifts in Focus as Madrid Professor Addresses SPIEF 2025 Opening Session 
June 20, 2025 23:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575